{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:38:25Z","timestamp":1792492705951,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.psychres.2014.12.003","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T22:43:29Z","timestamp":1423608209000},"page":"114-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Obsessive\u2013compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults"],"prefix":"10.1016","volume":"227","author":[{"given":"Naomi A.","family":"Fineberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Reghunandanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen B.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitender","family":"Sareen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Sookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2014.12.003_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.psychres.2014.12.003_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"Suppl.","key":"10.1016\/j.psychres.2014.12.003_bib3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1600-0447.1978.tb02357.x","article-title":"A comprehensive psychopathological rating scale","volume":"271","author":"\u00c5sberg","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive\u2013compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-200204000-00007","article-title":"Sertraline and fluoxetine treatment of obsessive compulsive disorder: results of a double-blind, 6-month treatment study","volume":"22","author":"Bergeron","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1016\/j.psychres.2014.12.003_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jpsychires.2013.03.022","article-title":"Repetitive transcranial magnetic stimulation (rTMS) for obsessive\u2013compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials","volume":"47","author":"Berlim","year":"2013","journal-title":"Journal of Psychiatric Research"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive\u2013compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib9","unstructured":"Biotechnologyevents.com:Transcept Pharmaceuticals Inc. \u3008http:\/\/www.Biotechnologyevents.com\u3009; 2013 (accessed 4.06.13.)."},{"issue":"7","key":"10.1016\/j.psychres.2014.12.003_bib10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive\u2013compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Molecular Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2014.12.003_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose\u2013response relationship of SSRI in obsessive\u2013compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Molecular Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2014.12.003_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive\u2013compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11920-011-0205-3","article-title":"Update on repetitive transcranial magnetic stimulation in obsessive compulsive disorder: different targets","volume":"13","author":"Blom","year":"2011","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.psychres.2014.12.003_bib14","first-page":"29","article-title":"Mechanisms of deep brain stimulation in for obsessive compulsive disorder: effects upon cells and circuits","volume":"6","author":"Bourne","year":"2012","journal-title":"Frontiers in Integrative Neurosciences"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib1001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/pgs.11.133","article-title":"Pharmacogenetics of obsessive-compulsive disorder","volume":"13","author":"Brandl","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","article-title":"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive\u2013compulsive disorder","volume":"14","author":"Brandl","year":"2014","journal-title":"Pharmacogenomics Journal"},{"issue":"11","key":"10.1016\/j.psychres.2014.12.003_bib16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder: a double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1016\/j.psychres.2014.12.003_bib17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4088\/JCP.v59n0907d","article-title":"Gabapentin augmentation for fluoxetine-treated patients with obsessive\u2013compulsive disorder","volume":"59","author":"Cor\u00e1-Locatelli","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive\u2013compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1017\/S1092852912000491","article-title":"Clinical features of tic-related obsessive\u2013compulsive disorder: results from a large multicenter study","volume":"17","author":"de Alvarenga","year":"2012","journal-title":"CNS Spectrums"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/schbul\/sbr077","article-title":"The 5-year course of obsessive\u2013compulsive symptoms and obsessive\u2013compulsive disorder in first-episode schizophrenia and related disorders","volume":"39","author":"de Haan","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11920-011-0200-8","article-title":"Current status of deep brain stimulation for obsessive\u2013compulsive disorder: a clinical review of different targets","volume":"13","author":"de Koning","year":"2011","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/15622970903418544","article-title":"Duration of untreated illness as a predictor of treatment response and remission in obsessive\u2013compulsive disorder","volume":"11","author":"Dell\u2019Osso","year":"2010","journal-title":"World Journal of Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0165-0327(00)00225-1","article-title":"Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine","volume":"65","author":"Demyttenaere","year":"2001","journal-title":"Journal of Affective Disorders"},{"issue":"8","key":"10.1016\/j.psychres.2014.12.003_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive\u2013compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double blind comparison of venlafaxine and paroxetine in obsessive\u2013compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3928\/0048-5713-19890201-11","article-title":"Treatment of obsessive compulsive disorder with clomipramine","volume":"19","author":"DeVeaugh-Geiss","year":"1989","journal-title":"Psychiatric Annals"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","article-title":"A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive\u2013compulsive disorder","volume":"31","author":"Diniz","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.psychres.2014.12.003_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.psychres.2010.10.031","article-title":"The Cognitive Assessment Instrument of Obsessions and Compulsions (CAIOC)","volume":"187","author":"Dittrich","year":"2011","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/YIC.0b013e32833119d8","article-title":"Open-label study of high (30mg) and moderate (20mg) dose escitalopram for the treatment of obsessive\u2013compulsive disorder","volume":"24","author":"Dougherty","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0924-977X(95)90660-6","article-title":"Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine","volume":"5","author":"Dunbar","year":"1995","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4088\/JCP.12m07657","article-title":"Five-year course of obsessive\u2013compulsive disorder: predictors of remission and relapse","volume":"74","author":"Eisen","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2014.12.003_bib33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archpsyc.55.10.918","article-title":"Intravenous clomipramine for obsessive\u2013compulsive disorder refractory to oral clomipramine: a placebo-controlled study","volume":"55","author":"Fallon","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2014.12.003_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4088\/JCP.12m07789","article-title":"Treatment response, symptom remission and wellness in obsessive\u2013compulsive disorder","volume":"74","author":"Farris","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib35","unstructured":"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. MedWatch. \u3008www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm\u3009; 2011 (accessed 6.04.13.)."},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1192\/apt.bp.109.007237","article-title":"Pharmacotherapy for obsessive\u2013compulsive disorder","volume":"17","author":"Fineberg","year":"2011","journal-title":"Advances in Psychiatric Treatment"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mppsy.2007.04.001","article-title":"Pharmacological treatment of obsessive\u2013compulsive disorder","volume":"6","author":"Fineberg","year":"2007","journal-title":"Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive\u2013compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib39","first-page":"1","article-title":"Evidence-based pharmacotherapy of obsessive\u2013compulsive disorder","volume":"9","author":"Fineberg","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13651501.2013.777745","article-title":"Lifetime comorbidity of obsessive\u2013compulsive disorder and sub-threshold obsessive\u2013compulsive symptomatology in the community: impact, prevalence, socio-demographic and clinical characteristics","volume":"17","author":"Fineberg","year":"2013","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/13651501.2013.777744","article-title":"Remission of obsessive\u2013compulsive disorders and syndromes; evidence from a prospective community cohort study over 30 years","volume":"17","author":"Fineberg","year":"2013","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib42","first-page":"151","article-title":"Clinical screening for obsessive\u2013compulsive and related disorders","volume":"45","author":"Fineberg","year":"2008","journal-title":"Israel Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/YIC.0b013e32825ea312","article-title":"Sustained response versus relapse: the pharmacotherapeutic goal for obsessive compulsive disorder","volume":"22","author":"Fineberg","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0004867412461958","article-title":"Pharmacotherapy of obsessive\u2013compulsive disorder: evidence-based treatment and beyond","volume":"47","author":"Fineberg","year":"2013","journal-title":"Australia and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euroneuro.2006.11.005","article-title":"Escitalopram prevents relapse of obsessive\u2013compulsive disorder","volume":"17","author":"Fineberg","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.12m08017","article-title":"Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive\u2013compulsive disorder","volume":"74","author":"Foa","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The Obsessive\u2013Compulsive Inventory: development and validation of a short version","volume":"14","author":"Foa","year":"2002","journal-title":"Psychological Assessment"},{"key":"10.1016\/j.psychres.2014.12.003_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-clinpsy-032511-143116","article-title":"Diagnosis and assessment of hoarding disorder","volume":"8","author":"Frost","year":"2012","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1016\/j.psychres.2014.12.003_bib49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1176\/appi.ajp.2008.08071006","article-title":"Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability and co-occurring psychiatric conditions","volume":"166","author":"Fullana","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biopsych.2006.03.083","article-title":"Examining the relationship between obsessive\u2013compulsive disorder and attention-deficit\/hyperactivity disorder in children and adolescents: a familial risk analysis","volume":"61","author":"Geller","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib51","series-title":"Obsessive Compulsive Disorder\u2014Current Science and Clinical Practice","first-page":"160","article-title":"Paediatric OCD: developmental aspects and treatment considerations","author":"Geller","year":"2012"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive\u2013compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.psychres.2014.12.003_bib53","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The Yale\u2013Brown Obsessive\u2013Compulsive Scale. 1: Reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib54","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale\u2013Brown Obsessive\u2013Compulsive Scale. 2: Validity","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib55","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/npp.2013.343","article-title":"Twelve-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive\u2013compulsive disorder","volume":"39","author":"Grant","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib56","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/sj.npp.1301165","article-title":"Three-year outcomes in deep brain stimulation for highly resistant obsessive\u2013compulsive disorder","volume":"31","author":"Greenberg","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive\u2013compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib58","series-title":"ECDEU: Assessment Manual for Psychopharmacology\u2014Revised","year":"1976"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive\u2013compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00004714-199212000-00008","article-title":"Clomipramine, clonazepam, and clonidine treatment of obsessive\u2013compulsive disorder","volume":"12","author":"Hewlett","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/0954026021000046146","article-title":"Prevalence of obsessive\u2013compulsive disorder in the British nationwide survey of child mental health","volume":"15","author":"Heyman","year":"2003","journal-title":"International Review of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archpsyc.57.1.76","article-title":"Multicentre double-blind comparison of sertraline and desipramine for concurrent obsessive\u2013compulsive and major depressive disorders","volume":"57","author":"Hoehn-Saric","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S1092852900007239","article-title":"Psychosocial function and economic costs of obsessive compulsive disorder","volume":"3","author":"Hollander","year":"1998","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.psychres.2014.12.003_bib64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive\u2013compulsive disorder with paroxetine","volume":"64","author":"Hollander","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib65","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive\u2013compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib66","doi-asserted-by":"crossref","first-page":"784","DOI":"10.4088\/JCP.09m05911blu","article-title":"Quality of life outcomes in patients with obsessive\u2013compulsive disorder: relationship to treatment response and symptom relapse","volume":"71","author":"Hollander","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00436159","article-title":"D-Amphetamine in obsessive\u2013compulsive disorder","volume":"80","author":"Insel","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib68","first-page":"5","article-title":"Obsessive\u2013compulsive disorder: a double blind trial of clomipramine and clorgyline","volume":"46","author":"Insel","year":"1983","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/15622975.2011.575177","article-title":"Safety and efficacy of repetitive transcranial magnetic stimulation in obsessive compulsive disorder: a review","volume":"13","author":"Jaafari","year":"2012","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1176\/ajp.154.9.1261","article-title":"Placebo-controlled trial of fluoxetine and phenelzine for obsessive\u2013compulsive disorder","volume":"154","author":"Jenike","year":"1997","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib71","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1034\/j.1600-0447.2002.01261.x","article-title":"Addition of cognitive-behaviour therapy for obsessive\u2013compulsive disorder patients non-responding to fluoxetine","volume":"106","author":"Kampman","year":"2002","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"11","key":"10.1016\/j.psychres.2014.12.003_bib72","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive\u2013compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib73","unstructured":"Koran, L.M., Simpson, H.B., 2013. Guideline Watch: Practice Guideline for the Treatment of Patients with Obsessive\u2013Compulsive Disorder. \u3008http:\/\/psychiatryonline.org\/content.aspx?\u3009 bookid=28 & sectionid=40634994 (accessed 10.11.13.)."},{"key":"10.1016\/j.psychres.2014.12.003_bib74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive\u2013compulsive disorder: an open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1176\/appi.ajp.159.1.88","article-title":"Efficacy of sertraline in the long-term treatment of obsessive\u2013compulsive disorder","volume":"159","author":"Koran","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib76","volume":"2007","author":"Koran","year":"2007"},{"key":"10.1016\/j.psychres.2014.12.003_bib77","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/ajp.154.3.396","article-title":"Rapid benefit of intravenous pulse-loading of clomipramine in obsessive compulsive disorder","volume":"154","author":"Koran","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1475-3588.2009.00548.x","article-title":"Treatment-resistant obsessive\u2013compulsive disorder in young people: assessment and treatment strategies","volume":"15","author":"Krebs","year":"2010","journal-title":"Child and Adoescentl Mental Health"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib79","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive\u2013compulsive disorder: a review of the diagnostic criteria and possible sub-types and dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.psychres.2014.12.003_bib80","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00004583-200212000-00014","article-title":"Fluoxetine in children and adolescents with OCD: a placebo-controlled trial","volume":"41","author":"Liebowitz","year":"2002","journal-title":"Journal of American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib81","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200301000-00004","article-title":"Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: what if antipsychotic is discontinued?","volume":"18","author":"Maina","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","article-title":"Eight-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder","volume":"18","author":"Maina","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269881105053299","article-title":"Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long term open-label study","volume":"19","author":"Marazziti","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"20","key":"10.1016\/j.psychres.2014.12.003_bib84","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive\u2013compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.psychres.2014.12.003_bib85","first-page":"1","article-title":"The Expert Consensus Guideline series. Treatment of obsessive\u2013compulsive disorder","volume":"58","author":"March","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib86","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.comppsych.2011.01.001","article-title":"Longitudinal course of obsessive\u2013compulsive disorder in patients with anxiety disorders: a 15-year prospective follow-up study","volume":"52","author":"Marcks","year":"2011","journal-title":"Comprehensive Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib87","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/da.20693","article-title":"Hoarding disorder: a new diagnosis for DSM-V?","volume":"27","author":"Mataix-Cols","year":"2010","journal-title":"Depression and Anxiety"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib88","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","article-title":"A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive\u2013compulsive disorder","volume":"70","author":"Matsunaga","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib89","first-page":"E10","article-title":"Deep brain stimulation for obsessive\u2013compulsive disorder: past, present, and future","volume":"29","author":"Milan","year":"2010","journal-title":"Journal of Neurosurgery"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib90","first-page":"189","article-title":"Clomipramine in obsessional neurosis: a placebo-controlled trial","volume":"1","author":"Montgomery","year":"1980","journal-title":"Pharmacological Medicine"},{"key":"10.1016\/j.psychres.2014.12.003_bib91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20mg, 40mg, and 60mg are all effective and well tolerated compared with placebo in obsessive\u2013compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind placebo-controlled study of fluoxetine in patients with DSM-IIIR obsessive compulsive disorder","volume":"3","author":"Montgomery","year":"1993","journal-title":"European Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.psychres.2014.12.003_bib93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant ocd: a double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectrums"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31887\/DCNS.2010.12.1\/dmrazek","article-title":"Psychiatric pharmacogenomic testing in clinical practice","volume":"12","author":"Mrazek","year":"2010","journal-title":"Dialogues in Clinical Neurosciences"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib95","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0269881108089582","article-title":"Obsessive\u2013compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern","volume":"23","author":"Mukhopadhaya","year":"2009","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004714-199708000-00005","article-title":"Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive\u2013compulsive disorder; a single-blind study","volume":"17","author":"Mundo","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1016\/j.psychres.2014.12.003_bib97","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1469-7610.2011.02434.x","article-title":"Children with very early onset obsessive\u2013compulsive disorder: clinical features and treatment outcome","volume":"52","author":"Nakatani","year":"2011","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib98","unstructured":"National Institute of Clinical Excellence (NICE), 2006. Obsessive\u2013Compulsive Disorder: Core Interventions in the Treatment of Obsessive\u2013Compulsive Disorder and Body Dysmorphic Disorder. Available at: \u3008http:\/\/www.nice.org.uk\/nicemedia\/pdf\/cg031fullguideline.pdf\u3009; (accessed 19.11.11.)."},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v67n0103","article-title":"High-dose sertraline strategy for nonresponders to acute treatment for obsessive\u2013compulsive disorder: a multicenter double-blind trial","volume":"67","author":"Ninan","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0b013e3283466657","article-title":"Pregabalin augmentation in treatment-resistant obsessive\u2013compulsive disorder","volume":"26","author":"Oulis","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0924-9338(99)80725-1","article-title":"Citalopram for treatment-resistant obsessive\u2013compulsive disorder","volume":"14","author":"Pallanti","year":"1999","journal-title":"European Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2014.12.003_bib103","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0269881109104850","article-title":"High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey","volume":"24","author":"Pampaloni","year":"2010","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.31887\/DCNS.2010.12.2\/dpauls","article-title":"The genetics of obsessive\u2013compulsive disorder: a review","volume":"12","author":"Pauls","year":"2010","journal-title":"Dialogues in Clinical Neurosciences"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1176\/ajp.152.1.76","article-title":"A family study of obsessive\u2013compulsive disorder","volume":"152","author":"Pauls","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib106","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0269881108099215","article-title":"Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive\u2013compulsive symptoms","volume":"24","author":"Poyurovsky","year":"2010","journal-title":"Journal of Psychopharmacology"},{"issue":"14","key":"10.1016\/j.psychres.2014.12.003_bib107","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","article-title":"Obsessive\u2013compulsive disorder in schizophrenia: clinical characteristics and treatment","volume":"18","author":"Poyurovsky","year":"2004","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib108","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Current Opinion in Endocrinology Diabetes and Obesity"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0b013e3282f0f0c5","article-title":"High-dose escitalopram for the treatment of obsessive\u2013compulsive disorder","volume":"23","author":"Rabinowitz","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004850-199711000-00003","article-title":"A 2-year study of sertraline in the treatment of obsessive\u2013compulsive disorder","volume":"12","author":"Rasmussen","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","article-title":"Fluvoxamine for children and adolescents with obsessive\u2013compulsive disorder: a randomized, controlled, multicenter trial","volume":"40","author":"Riddle","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib112","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archpsyc.1984.01790210031005","article-title":"Lifetime prevalence of specific psychiatric disorders in three sites","volume":"41","author":"Robins","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2014.12.003_bib113","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive\u2013compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004714-200102000-00009","article-title":"Long-term treatment of obsessive\u2013compulsive disorder after an acute response: a comparison of fluoxetine versus placebo","volume":"21","author":"Romano","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.mp.4001798","article-title":"The Dimensional Yale\u2013Brown Obsessive\u2013Compulsive Scale (DY\u2013BOCS): an instrument for assessing obsessive\u2013compulsive symptom dimensions","volume":"11","author":"Rosario-Campos","year":"2006","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib116","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1176\/appi.ajp.160.3.513","article-title":"Capsulotomy for refractory anxiety disorders: long-term follow-up of 26 patients","volume":"160","author":"Ruck","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib117","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive\u2013compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e3181c8272a","article-title":"Predictors of adherence among patients with obsessive\u2013compulsive disorder undergoing naturalistic pharmacotherapy","volume":"30","author":"Santana","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib119","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jclp.20792","article-title":"Pharmacotherapy of compulsive hoarding","volume":"67","author":"Saxena","year":"2011","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1016\/j.psychres.2014.12.003_bib120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","article-title":"Clozapine-induced obsessive\u2013compulsive symptoms in schizophrenia: a critical review","volume":"10","author":"Schirmbeck","year":"2012","journal-title":"Current Neuropharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib121","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/WNF.0b013e31823429bd","article-title":"Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia","volume":"34","author":"Sch\u00f6nfelder","year":"2011","journal-title":"Clinical Neuropharmacology"},{"issue":"10","key":"10.1016\/j.psychres.2014.12.003_bib122","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2014.12.003_bib123","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"International Clinical Psychopharmacology"},{"issue":"20","key":"10.1016\/j.psychres.2014.12.003_bib124","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2014.12.003_bib125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/da.20691","article-title":"ADHD prevalence and association with hoarding behaviors in childhood-onset OCD","volume":"27","author":"Sheppard","year":"2010","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.psychres.2014.12.003_bib126","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2012.11.JNS12389","article-title":"Limbic system surgery for treatment-refractory obsessive\u2013compulsive disorder: a prospective long-term follow-up of 64 patients","volume":"118","author":"Sheth","year":"2013","journal-title":"Journal of Neurosurgery"},{"issue":"5","key":"10.1016\/j.psychres.2014.12.003_bib127","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.2007.07091440","article-title":"A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive\u2013compulsive disorder","volume":"165","author":"Simpson","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20052","article-title":"Standard criteria for relapse are needed in obsessive\u2013compulsive disorder","volume":"21","author":"Simpson","year":"2005","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4088\/JCP.v67n0214","article-title":"Response versus remission in obsessive\u2013compulsive disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","article-title":"A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive\u2013compulsive disorder","volume":"25","author":"Soltani","year":"2010","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib131","series-title":"Treatment Resistant Anxiety Disorders: Resolving Impasses to Symptom Remission","first-page":"31","article-title":"Specialized cognitive behavior therapy for treatment resistant obsessive\u2013compulsive disorder","author":"Sookman","year":"2010"},{"key":"10.1016\/j.psychres.2014.12.003_bib132","first-page":"1","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive\u2013compulsive disorder (OCD)","volume":"23","author":"Soomro","year":"2008","journal-title":"Cochrane Database Systematic Review"},{"key":"10.1016\/j.psychres.2014.12.003_bib133","unstructured":"Stahl, S. (Ed.), 2008. Antidepressants. In: Stahl\u05f3s Essential Psychopharmacology\u2014Neuroscientific Basis and Practical Applications. Cambridge University Press, Cambridge, UK, pp.. 511\u2013666."},{"issue":"4","key":"10.1016\/j.psychres.2014.12.003_bib134","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive\u2013compulsive disorder: a randomised, placebo-controlled, paroxetine referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S1092852900016722","article-title":"Escitalopram in obsessive\u2013compulsive disorder: response of symptom dimensions to pharmacotherapy","volume":"13","author":"Stein","year":"2008","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.psychres.2014.12.003_bib136","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0005-7967(96)00036-8","article-title":"The Yale\u2013Brown Obsessive Compulsive Scale: interview versus self-report","volume":"34","author":"Steketee","year":"1996","journal-title":"Behaviour Research and Therapy"},{"issue":"2","key":"10.1016\/j.psychres.2014.12.003_bib137","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YIC.0b013e32835bd24e","article-title":"Escitalopram in the treatment of patients with schizophrenia and obsessive\u2013compulsive disorder: an open-label, prospective study","volume":"28","author":"Stryjer","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib138","first-page":"257","article-title":"Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data","volume":"57","author":"Szegedi","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2014.12.003_bib139","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4088\/JCP.v66n0913","article-title":"Behavior therapy augments response of patients with obsessive\u2013compulsive disorder responding to drug treatment","volume":"66","author":"Tenneij","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2014.12.003_bib140","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.v65n0708","article-title":"Cognitive-behavioral therapy for medication nonresponders with obsessive\u2013compulsive disorder: a wait-list-controlled open trial","volume":"65","author":"Tolin","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib141","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive\u2013compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2014.12.003_bib142","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4088\/JCP.v68n1013","article-title":"Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive\u2013compulsive disorder: a naturalistic study","volume":"68","author":"Tundo","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2014.12.003_bib143","first-page":"603","article-title":"Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor, in the treatment of obsessive\u2013compulsive disorder: a double blind placebo-controlled trial","volume":"19","author":"Ushijima","year":"1997","journal-title":"Japanese Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib144","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1016\/j.psychres.2014.12.003_bib145","first-page":"5","article-title":"The cross national epidemiology of obsessive compulsive disorder","volume":"55","author":"Weissman","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2014.12.003_bib146","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1464-410X.2012.11028.x","article-title":"The prevalence and natural history of urinary symptoms among recreational ketamine users","volume":"110","author":"Winstock","year":"2012","journal-title":"BJU International"},{"key":"10.1016\/j.psychres.2014.12.003_bib147","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.euroneuro.2005.04.012","article-title":"Size and burden of mental disorders in Europe\u2014a critical review","volume":"15","author":"Wittchen","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib148","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00004850-199300840-00015","article-title":"Pharmacotherapy of obsessive compulsive disorder: experience with fluoxetine","volume":"8","author":"Wood","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.12.003_bib149","series-title":"Clinical Description and Diagnostic Guidelines","article-title":"The ICD-10 classification of mental and behavioural disorders","year":"1992"},{"issue":"6","key":"10.1016\/j.psychres.2014.12.003_bib150","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","article-title":"Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40mg","volume":"170","author":"Zivin","year":"2013","journal-title":"American Journal of Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811400986X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811400986X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T03:14:11Z","timestamp":1651202051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016517811400986X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S016517811400986X"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2014.12.003","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obsessive\u2013compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}